

Philippe Pourquier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/156051/publications.pdf>

Version: 2024-02-01

66
papers

3,919
citations

159358

30
h-index

118652

62
g-index

75
all docs

75
docs citations

75
times ranked

4228
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998, 1400, 83-106.	2.4	476
2	Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. <i>Nature Medicine</i> , 2001, 7, 961-966.	15.2	339
3	Gadd45, a p53-Responsive Stress Protein, Modifies DNA Accessibility on Damaged Chromatin. <i>Molecular and Cellular Biology</i> , 1999, 19, 1673-1685.	1.1	251
4	Topoisomerase I-mediated DNA damage. <i>Advances in Cancer Research</i> , 2001, 80, 189-216.	1.9	182
5	Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages. <i>Journal of Biological Chemistry</i> , 1999, 274, 8516-8523.	1.6	168
6	Effects of Uracil Incorporation, DNA Mismatches, and Abasic Sites on Cleavage and Religation Activities of Mammalian Topoisomerase I. <i>Journal of Biological Chemistry</i> , 1997, 272, 7792-7796.	1.6	164
7	Topoisomerase I inhibitors: selectivity and cellular resistance. <i>Drug Resistance Updates</i> , 1999, 2, 307-318.	6.5	158
8	Trapping of Mammalian Topoisomerase I and Recombinations Induced by Damaged DNA Containing Nicks or Gaps. <i>Journal of Biological Chemistry</i> , 1997, 272, 26441-26447.	1.6	153
9	The Chemistry of Wine Polyphenolic C-Glycosidic Ellagitannins Targeting Human Topoisomerase II. <i>Chemistry - A European Journal</i> , 2005, 11, 6503-6513.	1.7	130
10	Mechanisms of Camptothecin Resistance by Human Topoisomerase I Mutations. <i>Journal of Molecular Biology</i> , 2004, 339, 773-784.	2.0	129
11	Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 1885-1890.	3.3	100
12	Predicting drug response and toxicity based on gene polymorphisms. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 171-196.	2.0	96
13	From old alkylating agents to new minor groove binders. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 43-61.	2.0	96
14	The DNA polymerase β is required for the repair of non-compatible DNA double strand breaks by NHEJ in mammalian cells. <i>Nucleic Acids Research</i> , 2006, 34, 2998-3007.	6.5	90
15	Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. <i>Clinical Cancer Research</i> , 2002, 8, 2499-504.	3.2	82
16	Targeting the genetic alterations of the PI3K/AKT/mTOR pathway: Its potential use in the treatment of bladder cancers. , 2015, 145, 1-18.		75
17	Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma. <i>Cancer Research</i> , 2011, 71, 1041-1049.	0.4	72
18	Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 2040-2045.	3.3	65

#	ARTICLE	IF	CITATIONS
19	DNA Protein Cross-Links Produced by NSC 652287, a Novel Thiophene Derivative Active Against Human Renal Cancer Cells. <i>Molecular Pharmacology</i> , 1999, 56, 478-484.	1.0	63
20	Apoptotic Topoisomerase I-DNA Complexes Induced by Staurosporine-mediated Oxygen Radicals. <i>Journal of Biological Chemistry</i> , 2004, 279, 50499-50504.	1.6	62
21	Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines. <i>Molecular Pharmacology</i> , 1999, 56, 77-84.	1.0	58
22	<i>ERCC5</i> , <i>XPG</i> , <i>ERCC1</i> and <i>BRCA1</i> gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. <i>Cancer</i> , 2011, 117, 3445-3456.	2.0	57
23	New Topoisomerase I mutations are associated with resistance to camptothecin. <i>Molecular Cancer</i> , 2011, 10, 64.	7.9	56
24	Single helically folded aromatic oligoamides that mimic the charge surface of double-stranded B-DNA. <i>Nature Chemistry</i> , 2018, 10, 511-518.	6.6	56
25	Interaction of Human Nuclear Topoisomerase I with Guanosine Quartet-forming and Guanosine-rich Single-stranded DNA and RNA Oligonucleotides. <i>Journal of Biological Chemistry</i> , 2002, 277, 8906-8911.	1.6	51
26	Protein arginine methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins. <i>FEBS Letters</i> , 2008, 582, 1483-1489.	1.3	49
27	Human Apurinic/Apyrimidinic Endonuclease (Ape1) and Its N-terminal Truncated Form (AN34) Are Involved in DNA Fragmentation during Apoptosis. <i>Journal of Biological Chemistry</i> , 2003, 278, 37768-37776.	1.6	48
28	Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. <i>FEBS Journal</i> , 1993, 211, 141-146.	0.2	47
29	Induction of Topoisomerase I Cleavage Complexes by the Vinyl Chloride Adduct 1,N 6-Ethenoadenine. <i>Journal of Biological Chemistry</i> , 1998, 273, 27245-27249.	1.6	40
30	Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate. <i>Journal of Biological Chemistry</i> , 2000, 275, 15246-15253.	1.6	35
31	Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. <i>Nucleic Acids Research</i> , 1999, 27, 1919-1925.	6.5	34
32	The Polyphenolic Ellagitannin Vescalagin Acts As a Preferential Catalytic Inhibitor of the Î± Isoform of Human DNA Topoisomerase II. <i>Molecular Pharmacology</i> , 2012, 82, 134-141.	1.0	31
33	Inhibition of Topoisomerase I Cleavage Activity by Thiol-reactive Compounds. <i>Journal of Biological Chemistry</i> , 2007, 282, 14403-14412.	1.6	22
34	The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells. <i>PLoS ONE</i> , 2009, 4, e5493.	1.1	22
35	Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture. <i>Anti-Cancer Drugs</i> , 1996, 7, 738-744.	0.7	21
36	Structural Basis for Topoisomerase I Inhibition by Nucleoside Analogs. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2003, 22, 653-658.	0.4	20

#	ARTICLE	IF	CITATIONS
37	Redox mechanism of levobupivacaine cytostatic effect on human prostate cancer cells. <i>Redox Biology</i> , 2018, 18, 33-42.	3.9	19
38	Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients. <i>International Journal of Cancer</i> , 2006, 119, 1732-1735.	2.3	18
39	BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. <i>British Journal of Cancer</i> , 2015, 112, 688-692.	2.9	18
40	Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. <i>BMC Cancer</i> , 2018, 18, 194.	1.1	18
41	Differential over-expression of <i>mdr1</i> genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine. <i>International Journal of Cancer</i> , 1993, 55, 115-121.	2.3	17
42	Doxorubicin-Induced Alterations of c-myc and c-jun Gene Expression in Rat Glioblastoma Cells: Role of c-jun in Drug Resistance and Cell Death. <i>Biochemical Pharmacology</i> , 1998, 55, 1963-1971.	2.0	17
43	Differential Stabilization of Topoisomerase-II-DNA Cleavable Complexes by Doxorubicin and Etoposide in Doxorubicin-Resistant Rat Glioblastoma Cells. <i>FEBS Journal</i> , 1997, 245, 307-315.	0.2	16
44	Predicting drug response based on gene expression. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 51, 205-227.	2.0	15
45	Carboxylate-functionalized foldamer inhibitors of HIV-1 integrase and Topoisomerase 1: artificial analogues of DNA mimic proteins. <i>Nucleic Acids Research</i> , 2019, 47, 5511-5521.	6.5	15
46	Polymorphisms in <i>SLCO1B3</i> and <i>NR1I2</i> as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. <i>Pharmacogenomics</i> , 2015, 16, 1439-1450.	0.6	14
47	Deciphering the role of the <i>ERCC2</i> gene polymorphism on anticancer drug sensitivity. <i>Carcinogenesis</i> , 2012, 33, 962-968.	1.3	13
48	Association of <i>NR1I2</i> , <i>CYP3A5</i> and <i>ABCB1</i> genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 653-659.	1.1	13
49	The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor. <i>Cells</i> , 2020, 9, 1641.	1.8	13
50	Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. <i>Anti-Cancer Drugs</i> , 1995, 6, 135-146.	0.7	11
51	Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine. <i>Anti-Cancer Drugs</i> , 1998, 9, 245-254.	0.7	11
52	LINE-1 as a therapeutic target for castration-resistant prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1292-1309.	3.0	11
53	High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor. <i>Cells</i> , 2020, 9, 1469.	1.8	11
54	PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter <i>SLC16A1</i> . <i>Cancers</i> , 2021, 13, 3635.	1.7	10

#	ARTICLE	IF	CITATIONS
55	Elongation of oligonucleotide primers forming a triple helix on double-stranded DNA templates by purified DNA polymerases. <i>Biochemical and Biophysical Research Communications</i> , 2003, 311, 380-385.	1.0	8
56	Major Efficacy of Trabectedin in 2 Metastatic Osteosarcoma Patients with Wild-Type Asp1104 ERCC5 Tumor Status. <i>Onkologie</i> , 2013, 36, 670-673.	1.1	7
57	Prospective assessment of the predictive value of the <i>BRCA1</i> gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. <i>Cancer Medicine</i> , 2018, 7, 1575-1577.	1.3	6
58	Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells. <i>Pharmaceuticals</i> , 2021, 14, 624.	1.7	6
59	Review of Current Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>European Urology Supplements</i> , 2011, 10, e20-e25.	0.1	4
60	Gene Expression Signature Predicting High-Grade Prostate Cancer Responses to Oxaliplatin. <i>Molecular Pharmacology</i> , 2012, 82, 1205-1216.	1.0	4
61	Topoisomerase I and II Activity Assays. , 1999, 28, 95-110.		2
62	Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients. <i>Journal of Negative Results in BioMedicine</i> , 2015, 14, 18.	1.4	2
63	Safety and efficacy of tamsulosin as second-line treatment for patients with recurrent bladder cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 304-304.	0.8	2
64	De nouveaux rôles pour l'ADN topo-isomérase I. <i>Medecine/Sciences</i> , 2002, 18, 975-981.	0.0	1
65	DNA Topoisomerase I and Illegitimate Recombination. <i>Cancer Drug Discovery and Development</i> , 2012, , 119-143.	0.2	0
66	Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5701.	1.8	0